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Abstract  25 
Objective - To explore the separate effects of being at risk of gestational diabetes mellitus (GDM) and 26 
screening for GDM, and of raised fasting plasma glucose (FPG) and clinical diagnosis of GDM, on the 27 
risk of late stillbirth. 28 
Design - Prospective case-control study. 29 
Setting – 41 maternity units in the United Kingdom. 30 
Population - Women who had a stillbirth ≥28 weeks’ gestation (n=291) and women with an ongoing 31 
pregnancy at the time of interview (n=733). 32 
Methods - Causal mediation analysis explored the joint effects of 1) ‘at risk’ of GDM and screening for 33 
GDM and 2) raised FPG (≥5·6mmol/L) and clinical diagnosis of GDM on the risks of late stillbirth. 34 
Adjusted odds ratios (aOR) were estimated by logistic regression adjusted for confounders identified 35 
by directed acyclic graphs.  36 
Main outcome measures – Screening for GDM and FPG levels 37 
Results -Women 'at risk' of GDM, but not screened, experienced 44% greater risk of late stillbirth than 38 
those not at risk (aOR=1·44 95%CI=1·01-2·06). Women ‘at risk’ of GDM who were screened 39 
experienced no such increase (aOR=0·98, 95%CI=0·70-1·36). Women with raised FPG not diagnosed 40 
with GDM experienced four-fold greater risk of late stillbirth than women with normal FPG (aOR=4·22, 41 
95%CI=1·04-17·02). Women with raised FPG who were diagnosed with GDM experienced no such 42 
increase (aOR=1·10 95%CI=0·31-3·91). 43 
Conclusions - Optimal screening and diagnosis of GDM mitigates higher risks of late stillbirth in women 44 
at risk of GDM and/or with raised FPG. Failure to diagnose GDM leaves women with raised FPG 45 
exposed to avoidable risk of late stillbirth.  46 
Funding – The Midland and North of England Stillbirth Study was funded by grant GN2156 from Action 47 
Medical Research, Cure Kids and Sands. 48 
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Tweetable abstract: Risk of #stillbirth in gestational diabetes is mitigated by effective screening and 50 
diagnosis. 51 
 52 
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Introduction 64 
The prevalence of stillbirth in the United Kingdom (UK) is above the European average, affecting 65 
almost one in three hundred pregnancies after 28 weeks of pregnancy.[1] Though likely influenced by 66 
a higher burden of population risk factors, such as obesity and cigarette smoking, a recent Confidential 67 
Enquiry concluded that up to 60% of antepartum stillbirths could have been prevented with improved 68 
antenatal care.[2] Of particular concern was a lack of consistent adherence to the National Institute 69 
for Health and Care Excellence (NICE) guidelines for the screening and diagnosis of gestational 70 
diabetes (GDM) [3]. Early identification and appropriate management of GDM has been considered 71 
an important factor in reducing the burden of adverse perinatal outcome.[4, 5] Hence, the 72 
Confidential Enquiry recommended an increased focus on the detection and management of GDM.[2] 73 
Pre-existing diabetes in pregnancy is associated with a four-to-six-fold increase in the risk of 74 
stillbirth.[6] The relationship between GDM and stillbirth is more complex; with no consensus in the 75 
relationship between GDM and risk of stillbirth.[4, 7-8] These studies employed a range of diagnostic 76 
criteria for GDM and there is inconsistency as to whether or not they included women who were 77 
diagnosed with GDM or who, retrospectively, met the criteria for GDM diagnosis. 78 
There is variation in recommendations regarding which women should be screened for GDM as well 79 
as differences in the criteria used for the diagnosis of GDM.[9, 10] In the UK, the 2015 NICE guidelines 80 
advise selected screening for GDM and the criteria recommended for GDM diagnosis are 81 
FPG≥5·6mmol/L or 2-hour glucose on the OGTT≥7·8mmol/L, which differs from the World Health 82 
Organisation (WHO) recommendations ( ≥5·1 mmol/L and ≥8·5mmol/L) [3, 10].The rationale for this 83 
was to balance the benefits of increased detection of women with a higher risk of adverse outcomes 84 
with the health economics relating to the cost and capacity limits of antenatal care provision.[11] To 85 
date there has been no assessment of the impact of the thresholds recommended by NICE, nor on the 86 
impact of screening practice in the UK on the prevalence of late stillbirth. We aimed to investigate the 87 
joint and separate effects of 1) being at risk of GDM and receiving blood glucose screening for GDM 88 
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and 2) hyperglycaemia and diagnosis of GDM (as a proxy for receiving specialised diabetes care) on 89 
the risk of late stillbirth in a large case-control study from across England. 90 
 91 
Methods 92 
Population and sample 93 
The Midlands and North of England Stillbirth Study (MiNESS) is a case-control study of singleton non-94 
anomalous late stillbirths (≥28 weeks’ gestation) and controls with ongoing pregnancies which ended 95 
in live births that were recruited in 41 maternity units in the UK between April 2014 and March 2016. 96 
It was principally established to explore the association between modifiable factors including maternal 97 
going-to-sleep position and the risk of late stillbirth.[12] The study was registered on 98 
www.clinicaltrials.gov (NCT02025530) and the protocol was published before data collection was 99 
complete.[13] Ethical and research approvals were obtained (Ref 13/NW/0874) on 20/01/14, with all 100 
participants providing written consent to take part in the study. MiNESS arose from the parent-led 101 
Stillbirth Summit in Minneapolis in 2011 [14] and a Priority Setting Partnership which included input 102 
from over 550 parents and members of the public. However, there was no active patient involvement 103 
in data analyses or interpretation of this secondary analysis. 104 
Inclusion and exclusion criteria 105 
Full details of the study are available elsewhere.[12] Briefly, cases were stillbirths occurring in 106 
singleton pregnancies ≥28 complete weeks’ of gestation. Prior to their discharge from the maternity 107 
unit eligible women were given information about the study and asked whether a researcher (who 108 
was also either a midwife or a nurse) could contact them to discuss the study. If the woman agreed, 109 
the researcher contacted her separately and, if consent was given to participate, an appointment for 110 
an interview was made. Participants were interviewed by research midwives or nurses at each site. 111 
Controls were women with an ongoing pregnancy at a similar gestational age to the cases. Controls 112 
were randomly selected (using a computer-generated sequence of random numbers) from the 113 
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booking lists of each participating maternity unit based (on a 2:1 ratio) on the number and gestation 114 
of late stillbirths in the previous four years in that hospital. Controls were introduced to the study by 115 
their community midwife or a research midwife and a similar consent process to the cases was carried 116 
out. Multiple pregnancies or pregnancies complicated by congenital anomaly were not eligible for 117 
recruitment, neither were pregnancies where the mother was aged under 16 years or could not give 118 
informed consent.[13] Pregnancies where the mother had pre-existing (type 1 or type 2) diabetes 119 
were also excluded from the current sample.  120 
Analyses 121 
The separate effects of being 'at risk' of GDM and receiving blood glucose screening for GDM (and all 122 
consequences thereof) on the risk of stillbirth were examined by causal mediation analysis in the total 123 
study sample (N=1012).[15] This approach, rooted in the potential outcome framework, involves 124 
examining how the occurrence of an outcome (Y) varies with more than one exposure, such as an 125 
exposure (Y|X=x = Yx) and mediator (Y|X=x, M=m = YxMm). This enables the distinct and joint effects of the 126 
exposure and mediator to be estimated.  127 
A composite exposure variable denoting 'at risk' of GDM was constructed from four of the five NICE 128 
recommended criteria for blood glucose screening for GDM, with 'at risk' defined as any of South Asian 129 
or Black Caribbean ethnicity, BMI ≥30kg/m2, or previous pregnancy effected by GDM or macrosomic 130 
(≥4·5kg) birth.[3] Data were not available on the fifth criterion, family history of GDM. The effects of 131 
both the exposure and mediator on the relative risk ratio of late stillbirth were estimated from odds 132 
ratios (ORs) calculated by logistic regression. 'At risk' of GDM was the principal exposure and receipt 133 
of screening for GDM was the principal mediator. Interactions terms were omitted due to negligible 134 
evidence of effect (p-for-interaction=0.932). Confounding variables were identified by specifying 135 
directed acyclic graphs (DAGs) (Figure S1). No variables were considered appropriate for adjustment 136 
as all partial confounding variables were concurrent partial mediators. 137 
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The separate effects of hyperglycaemia and diagnosis of GDM (as a proxy for receiving specialist 138 
diabetes care) on the risk of stillbirth were also examined by causal mediation analysis in all women 139 
who were screened for GDM (N=371). FPG was chosen as the measure of underlying glycaemic 140 
control, because 31.3% (n=5/16) of screened participants with an FPG≥5·6mmol/L were not clinically 141 
diagnosed with GDM during pregnancy, compared with just 5.9% (n=2/34) of those with a 2-hour 142 
OGTT≥7·8mmol/L). This variation in practice allows the distinct effects of the underlying glycaemic 143 
control and subsequent clinical diagnosis with GDM to be explored; as different combinations of both 144 
the exposure and mediator can be observed. FPG concentration was the principal exposure and clinical 145 
diagnosis of GDM was the principal mediator. Two models were evaluated; to explore FPG as a binary 146 
variable and continuous variable. Binary FPG concentration was defined using the 2015 NICE criteria 147 
for GDM diagnosis into 'normal' (FPG<5·6mmol/L) and 'raised' (FPG≥5·6mmol/L). Prior to 2015, the 148 
NICE criteria for the diagnosis of GDM by FPG was ≥7·0mmol/L. The shape of the association between 149 
continuous FPG concentration and risk of late stillbirth was examined by locally-weighted scatterplot 150 
smoothing (LOWESS) (Figure 2). Interactions terms were again omitted due to negligible evidence of 151 
effect (p-for-interaction=0.772 for binary FPG, p=0.501 for continuous FPG). Our DAG (Figure S1) 152 
implied the following confounding variables required adjustment: maternal ethnicity, socio-economic 153 
circumstances, family history of GDM, height, weight, age, parity, previous histories of GDM and 154 
macrosomia, and smoking. Family history of GDM was however not known and is therefore a potential 155 
source of unobserved confounding. 156 
Adjusted odds ratios (aORs) for the following causal effects were estimated by combining marginal 157 
values within each multivariable logistic regression model (further descriptions of each are available 158 
in the glossary): 1) the natural effect (Y1Mm|y=1-Y0Mm|y=0), 2) the total effect (Y1M1-Y0M0), 3) the 159 
controlled direct effect (Y1M0-Y0M0), 4) the total indirect effect (Y1M1-Y1M0), and 5) the natural 160 
indirect effect ([Y1Mm|y=1-Y0Mm|y=0]-[Y1M0-Y0M0]). Causal effect estimates for mediators 'screening for 161 
GDM' and 'diagnosis with GDM' comprise all the consequences thereof. They should not therefore be 162 
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interpreted as the isolated effect of e.g. 'diagnosis', but as everything that 'diagnosis' typically effects 163 
(i.e. receipt of enhanced care and management).       164 
95% confidence intervals (95% CIs) were derived using the delta method. We do not report total causal 165 
effects decomposed into direct and indirect effects, since our exposures (harmful) and mediators 166 
(beneficial) act in opposite directions.  167 
Our primary results are derived from complete case analyses as data were available for 96·6% of total 168 
participants (N=978/1012) and 91·9% (N=341/371) of those screened for GDM. Sensitivity analyses 169 
were however conducted in multiply imputed data and negligible differences were observed (see 170 
Tables S1-4). For these sensitivity analyses; 50 datasets were generated via multivariate imputation 171 
by chained equations comprising case/control status, maternal age, height, weight, parity, education, 172 
ranked index of multiple deprivation (an area-based measure of socio-economic deprivation derived 173 
from the mother's residential postcode), ethnicity, country of birth, first language, FPG, 2-hour OGTT, 174 
and glycated haemoglobin concentrations, smoking and marital status, and previous histories of GDM 175 
and macrosomia. Point estimates and standard errors were summarised using Rubin's rule.  176 
Analyses were conducted using Stata 14·2 (Statacorp, College Station, TX, USA). Exact p-values are 177 
presented to indicate compatibility with null distributions but no null-hypothesis significance tests 178 
were performed.[16] The 'significance' of each estimate was instead evaluated by considering the 179 
clinical implications of each point estimate judged against the overall uncertainty. This corresponds 180 
with guidance from the American Statistical Association [17] and current practice in leading 181 
Epidemiology journals. E-values for the point estimate (E) and least extreme confidence limit (ELL) 182 
were also determined for the controlled direct effect and total indirect effect to indicate the average 183 
required effect for an unobserved confounder to explain the observed associations with the 184 
outcome.[18]  185 
A core outcomes set was not used in this analysis.Role of the funding source 186 
The Midland and North of England Stillbirth Study was funded by grant GN2156 from Action Medical 187 
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Research, Cure Kids and Sands. The funding sources had no role in: 1) the design or conduct of the 188 
study, 2) the collection, analysis, or interpretation of the data, or 3) the preparation of the manuscript 189 
and decision to submit for publication. 190 
 191 
Results 192 
Figure 1 shows the derivation of the study and analytical samples. 1024 women were recruited, 193 
including 291 cases and 733 controls. 2·8% (n=8/291) of cases and 0·6% (n=4/733) of controls had 194 
pre-existing diabetes and were excluded from this analysis.  195 
Table 1 describes the profile of the study population. Of the 1012 total participants (283 cases and 196 
729 controls), 94 cases and 277 controls were screened for GDM and 8 cases and 30 controls were 197 
clinically diagnosed with GDM. 35·9% (n=99/276) of the cases and 32·6% (n=231/709) of the controls 198 
had at least one of the four known NICE risk factors for GDM. 69·7% (n=69/99) of these 'at risk' cases 199 
and 76·6% (n=177/231) of these 'at risk' controls received screening for GDM (Figure 1). The 200 
proportion of 'at risk' women who received GDM screening varied between maternity units 201 
(median=85%, IQR=60-100, range=20-100, p<0·0001). Of those without a known NICE risk factor for 202 
GDM, 13·6% (n=24/177) of the cases and 19·3% (n=92/478) of the controls were screened for GDM 203 
for other unspecified reasons (likely family history of GDM). 74·3% (n=156/210) of obese women 204 
were screened for GDM, 74·7% (n=106/142) of those self-reporting as South Asian or Black 205 
Caribbean, 71·4% (n=5/7) with previous history of GDM, and 90·0% (n=9/10) with previous history of 206 
GDM.  207 
'At risk' of GDM, screening for GDM, and risk of late stillbirth 208 
Women known to be 'at risk' of GDM overall experienced only modestly increased risk of late stillbirth 209 
(aOR=1·17 95%CI=0·87-1·57) (Table 2). This separated into a harmful direct effect of being 'at risk' of 210 
GDM and a protective indirect effect of receiving screening for GDM. Women 'at risk' of GDM who did 211 
not receive blood glucose screening experienced nearly 50% higher risks of stillbirth than women 212 
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without a known risk factor (aOR=1·44 95%CI=1·01-2·06, E=2.24, ELL=1.11) (Table 2). In contrast, 213 
women 'at risk' of GDM who did receive blood glucose screening had similar risks to women without 214 
a known risk factor (aOR=0·98, 95%CI=0·70-1·36) (Table 2). The risk of late stillbirth was thus around 215 
one-third lower for those 'at risk' of GDM who received blood glucose screening compared with those 216 
'at risk' of GDM who were not screened (aOR=0·68, 95%CI=0·47-0·98, E=2.30, ELL=1.21) (Table 2). 217 
 218 
FPG concentration, clinical diagnosis of GDM, and risk of late stillbirth  219 
Overall, the risk of late stillbirth in women with a raised FPG was almost twice as high as in women 220 
with normal FPG (aOR=1·97, 95%CI=0·61-6·32, ) (Table 3). This separated into a harmful direct effect 221 
of raised FPG, and a protective indirect effect of being clinically diagnosed with GDM and receiving 222 
specialised antenatal care. Women with a raised FPG who were not diagnosed with GDM and 223 
therefore did not receive specialist care experienced four-times higher risks of stillbirth than 224 
(undiagnosed) women with normal FPG (aOR=4·22, 95%CI=1·04-17·02, E=7.91, ELL=1.24) (Table 3). In 225 
contrast, women with a raised FPG who were diagnosed with GDM and did receive specialist care had 226 
similar risks to women with normal FPG (aOR=1·10 95%CI=0·31-3·91, ) (Table 3). The risk of late 227 
stillbirth was thus around four-times lower for those with raised FPG who were clinically diagnosed 228 
with GDM, then those with raised FPG who were not clinically- diagnosed (aOR=0.26, 95%CI=0.07-229 
0.93, E=7.15, ELL=1.36) (Table 3). 230 
The effect of FPG concentration on the risk of late stillbirth was approximately linear (Figure 2). 231 
Without GDM diagnosis, each 1mmol/L increase in FPG was associated with 61% greater risk of late 232 
stillbirth (aOR=1·63, 95%CI=1·01-2·64). The OR of late stillbirth for a range of FPG values (relative to 233 
women with FPG<4·1mmol/L, not diagnosed with GDM) with and without diagnosis and treatment for 234 
GDM are shown in Table 4. 235 
 236 
Discussion 237 
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Main findings 238 
This large, multi-centre case-control study reveals the separate and competing effects of ‘risk’ of GDM 239 
and screening, and of hyperglycaemia and clinical diagnosis of GDM, on the risk of late stillbirth. Using 240 
causal mediation analysis, we show how the harmful effects of being 'at risk' of GDM and of raised 241 
FPG are mitigated by GDM screening and diagnosis respectively. 242 
Without screening, women 'at risk' of GDM (as per NICE criteria) experienced 47% greater risk of late 243 
stillbirth. For those who were screened, this excess was essentially eliminated. Similarly, without GDM 244 
diagnosis, women with raised FPG experienced a four-fold greater risk of late stillbirth. For those who 245 
were diagnosed this excess was no longer apparent. Since a third of women with an FPG≥5·6mmol/L 246 
did not receive a GDM diagnosis - partly due to the change in NICE guidance in 2015 - the overall risk 247 
of late stillbirth was still over two-times greater in women with a raised FPG.   248 
Strengths and limitations 249 
This is the first study to explore the separate and contrasting effects of underlying hyperglycaemia 250 
and diagnosis of GDM (with the presumed consequent enhanced care) on risk of late stillbirth. 251 
Information was collected on a large range of confounding variables which were identified using DAGs. 252 
Data were relatively complete,  96·6% for ethnicity, BMI, previous histories of GDM and macrosomia; 253 
and 91·9% for FPG among those screened. The results were also not materially different in sensitivity 254 
analyses that used multiple imputation, increasing confidence in the observed associations. 255 
All participants received routine care, thus less than a third were screened for GDM. It was therefore 256 
not possible to jointly examine the effects of screening, FPG concentration, and diagnosis in the full 257 
sample (n=1012). The results from our subsample (n=371) are therefore only representative of women 258 
with indications for screening and should not be generalised to all pregnant women. Unfortunately, 259 
we did not have complete information on the NICE criteria for screening, as family history of diabetes 260 
was not collected. Nor do we know the reasons why the quarter of women 'at risk' of GDM were not 261 
screened. Unrecorded differences in risk profile, or in the participant's engagement with health 262 
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services, may introduce bias. However, the observed differences in screening levels between 263 
maternity units suggest these may reflect true variations in UK clinical practice. 264 
Our analyses and interpretations focussed on effect estimates, not null-hypothesis significance tests, 265 
as the latter are strongly discouraged within observational studies [16]. There are hence no formal 266 
risks of type I or type II errors. For some subgroups, particularly women with diagnosed GDM, our 267 
sample included very small numbers, leading to substantial uncertainty that should be appreciated 268 
when interpreting absolute effect sizes.   269 
Causal mediation analysis makes several assumptions, including that the exposure(s) and mediator(s) 270 
have a causal effect on the outcome. We believe these are plausible, and our assumptions are clearly 271 
outlined in our DAGs (Figure S1). Nevertheless, for both GDM screening and diagnosis, the 272 
hypothesised effects depend on presumed enhanced clinical response to diagnosis, without which we 273 
would not expect to see a benefit.  274 
Unbiased estimates of causal effects require no unobserved confounding. Family history of GDM may 275 
therefore bias the estimated causal effects of FPG and diagnosis of GDM on risk of stillbirth. Mediation 276 
analyses are also highly susceptible to intermediate confounding from unobserved causes of both 277 
mediator(s) and outcome(s),[19] although we could not identify any such variables for the 278 
relationships examined. Our E-values suggest that considerable confounding would be necessary to 279 
explain the observed point estimates; although modest confounding could explain the conservative 280 
estimates from our lower confidence limits.  281 
Interpretation  282 
Few previous studies have explored the separate and contrasting effects of raised blood glucose, as a 283 
harmful exposure, and the receipt of specialised care, as a mitigating factor; making it difficult to 284 
meaningfully compare results. Our findings do however support previous studies which have 285 
suggested that a diagnosis of GDM leads to improved perinatal outcomes in women with raised blood 286 
glucose [5, 20]. Few studies have been large enough to explore a relationship with stillbirth specifically, 287 
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Aberg et al. (1997) found very little difference in the risk of stillbirth between women with and without 288 
diagnosed GDM (OR=1·33, 95%CI=0·64-2·77), but identified much higher risks of intrauterine death in 289 
the previous pregnancy of women subsequently diagnosed with GDM (OR=1.56, 95%CI=1.12-2.19) 290 
[21]. Similarly Kodoma at al. (2013) found that when new, more stringent GDM criteria, were 291 
retrospectively applied to a cohort of 318 stillbirths, the prevalence of GDM increased from 2.4% to 292 
13.5% in women who had unexplained stillbirths.[22] These studies support our observations that 293 
untreated hyperglycaemia confers a greater risk of stillbirth, which is greatly reduced by a clinical 294 
diagnosis with GDM.  295 
There continues to be debate about the merit of universal versus targeted screening [23] and the ideal 296 
threshold for the diagnosis of GDM. In our sample, 2·8% of cases and 5·1% of controls were diagnosed 297 
with GDM. Although prevalence proportions vary greatly between populations, proportions of ≥5% 298 
are usual,[24] suggesting potential under-diagnosis. This would correspond with findings from the 299 
2015 UK Confidential Enquiry into Term Antepartum Stillbirths [2]. The NICE criteria for the diagnosis 300 
of GDM however changed in 2015, during the conduct of this study, from FPG ≥7·0mmol/L to 301 
≥5·6mmol/L,[3,25] which may explain a lower prevalence. The NICE reportedly selected their new FPG 302 
criterion to reflect increases in perinatal morbidity, specifically large-for-gestational-age at lower 303 
levels of FPG, [11] although it remains higher than the FPG ≥5·1mmol/L threshold recommended by 304 
the International Association of Diabetes and Pregnancy Study Groups (IADPSG) [26]. 305 
For those 'at risk' of GDM, we found a linear effect of increasing FPG on the risk of late stillbirth, which 306 
is in line with the findings of a continuous relationship between blood glucose levels and adverse 307 
pregnancy in the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study.[27] Our data do not 308 
therefore support the biological justification of one threshold over another, instead suggesting that it 309 
may be best determined by a pragmatic balance of resources required for the increased antenatal 310 
workloads and health costs with more stringent GDM diagnostic criteria against the reduced costs of 311 
improved perinatal outcome.[28] Our results suggest that universal adherence to NICE guidelines for 312 
the screening and diagnosis of GDM would greatly reduce the excess risk of stillbirth due to raised FPG 313 
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in the population. To lower this risk further - especially in individuals on the border of diagnosis - it 314 
may also be worth considering a graded approach to the care and management of blood glucose 315 
control in pregnant women, rather than relying on a single diagnostic threshold. 316 
 317 
Conclusion 318 
Women 'at risk' of GDM and/or with raised FPG experience higher risk of late stillbirth. With 319 
appropriate screening, diagnosis, and the presumed management and care practices that result, these 320 
risks can be largely mitigated. However, variation in practice leaves many women with borderline 321 
hyperglycaemia exposed to avoidably elevated risk. If the UK is to improve its record for preventable 322 
stillbirth, and have a hope of achieving ambitious government targets [29] then all women 'at risk' of 323 
GDM and/or with raised FPG must receive the care recommended by NICE. Further research needs to 324 
address the economic and practical implications of implementing different thresholds of FPG to 325 
diagnose GDM.   326 
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Figure 1 Derivation of the study and analytic sample(s).  431 
 432 
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 433 
 434 
Figure 2: Unconditional odds ratio for late stillbirth across typical values of fasting plasma glucose 435 
(FPG), relative to women with FPG<4.1mmol/L. 436 
Dotted line indicates current FPG threshold recommended by NICE.[3]  437 
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Table 1. Risk factors, screening and FPG concentration   439 
 Total participants (N=1012) Screened for GDM (N=371) 
 N(%) N(%) 
             
 
Cases 
(N=283) 
Controls 
(N=729) 
All 
(N=1012) 
Cases 
(N=94) 
Controls 
(N=277) 
All 
(N=371) 
NICE GDM risk variables             
Ethnicity             
   White 227 (81.4) 590 (82.8) 817 (82.4) 60 (64.5) 182 (67.7) 242 (66.9) 
   South Asian 40 (14.3) 93 (13.0) 133 (13.4) 
 
5 
27 (29.0) 71 (26.4) 98 (27.1) 
   Black Caribbean 1 (0.4) 8 (1.1) 9 (0.9) 1 (1.1) 7 (3.4) 8 (2.2) 
   Other 11 (3.9) 22 (3.1) 33 (3.3) 5 (5.4) 9 (2.6) 14 (3.8) 
   Missing 4  16  20  1  8  9  
BMI (kg/m2)             
   <18.5 (underweight) 9 (3.2) 23 (3.2) 32 (3.2) 3 (3.2) 8 (2.9) 11 (3.0) 
   18.5-24.9 (recommended) 111 (39.9) 342 (47.5) 453 (45.4) 19 (20.2) 90 (33.0) 109 (29.7) 
   25-29.9 (overweight) 88 (31.7) 215 (29.9) 303 (30.4) 22 (23.4) 69 (25.3) 91 (24.8) 
   ≥30 (obese) 70 (25.2) 140 (19.4) 210 (21.0) 50 (53.2) 106 (38.8) 156 (42.5) 
   Missing 5  9  14  0  4  4  
Previous GDM             
   No 282 (99.6) 723 (99.2) 1005 (99.3) 93 (98.9) 273 (98.6) 366 (98.7) 
   Yes 1 (0.4) 6 (0.8) 7 (0.7) 1 (1.1) 4 (1.4) 5 (1.4) 
Previous macrosomic infant             
   No 282 (99.7) 720 (98.8) 1002 (99.0) 94 (100.0) 268 (96.8) 362 (97.6) 
   Yes 1 (0.4) 9 (1.2) 10 (1.0) 0 (0.0) 9 (3.3) 9 (2.4) 
'At risk' of GDMa             
   No 177 (64.1) 478 (67.4) 655 (66.5) 24 (25.8) 92 (34.2) 116 (32.0) 
   Yes 99 (35.9) 231 (32.6) 330 (33.5) 69 (74.2) 177 (65.8) 246 (68.0) 
   Missing 7  20  27  
1  8  9  
             
FPG concentration (mmol/L)             
   <4.10        17 (18.5) 51 (18.8) 68 (18.7) 
   4.10-4.59       44 (47.8) 129 (47.4) 173 (47.5) 
   4.60-5.09       21 (22.8) 62 (22.8) 83 (22.8) 
   5.10-5.59       3 (3.3) 21 (7.7) 24 (6.6) 
   5.60-6.09       3 (3.3) 5 (1.8) 8 (2.2) 
   ≥6.10       4 (4.4) 4 (1.5) 8 (2.2) 
   Missing       2  5  7  
GDM diagnosed             
   No       87 (92.6) 247 (89.2) 334 (90.0) 
   Yes 
 
      7 (7.5) 30 (10.8) 37 (10.0) 
 
 
             
aWomen known to be 'at risk' of GDM and who are indicated for screening comprise those who reported their 440 
ethnic origin as South Asian, black Caribbean, had body mass index≥30Kg/m2, or who had a previous pregnancy 441 
affected by gestational diabetes or macrosomic birth (>4·5kg). 442 
 443 
 444 
 445 
 446 
 447 
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Table 2 Estimated effects of 'at risk' of GDMa and screening for GDM on risk of late stillbirth 448 
Effect estimated 
Exposure regime Reference regime aORb (95% CI) 
E-value 
(lower CI) 
      Total effect  'At risk' of GDM  
+ screened for GDM 
Not 'at risk' + 
+ not screened 0·98 (0·70-1·36)  
Natural effect 'At risk' of GDM  
+ 'natural' chance of screening 
Not 'at risk' + 
+ not screened 1·17 (0·87-1·57)  
Controlled direct effect 'At risk' of GDM  
+ not screened for GDM 
Not 'at risk' + 
+ not screened 1·44 (1·01-2·06) 2.24 (1.11) 
Total indirect effect 'At risk' of GDM  
+ screened for GDM 
'At risk' of GDM + 
+ not screened 0·68 (0·47-0·97) 2.30 (1.21) 
Natural indirect effect 'At risk' of GDM  
+ 'natural' chance of screening 
'At risk' of GDM + 
+ not screened 0·81 (0·67-0·98)  
aKnown risk factors for GDM (indicated by NICE for blood glucose screening) comprise South Asian or black Caribbean 449 
ethnicity, body mass index≥30Kg/m2, and previous pregnancy affected by gestational diabetes or macrosomic birth (>4·5kg).   450 
bModels included the exposure ('at risk' of GDM) and mediator (screened for GDM) only, as all partial confounding variables 451 
were also partial mediators. 452 
 453 
Table 3 Estimated effects of FPG concentration and clinical diagnosis of GDM on risk of late stillbirth 454 
Effect estimated Exposure regime Reference regime aORa (95% CI) 
E-value 
(lower CI) 
      Total effect ≥5·6mmol/Lb  
+ diagnosed with GDM 
<5·6mmol/L  
+ Not diagnosed 1·10 (0·31-3·91)  
Natural effect ≥5·6mmol/Lb  
+ 'natural' chance of diagnosis 
<5·6mmol/L  
+ Not diagnosed 1·97 (0·61-6·32)  
Controlled direct effect ≥5·6mmol/Lb  
+ not diagnosed with GDM 
<5·6mmol/L  
+ Not diagnosed 4·22 (1·04-17·02) 7.91 (1.24) 
Total indirect effect ≥5·6mmol/Lb  
+ diagnosed with GDM 
≥5·6mmol/Lb  
+ Not diagnosed 0·26 (0·07-0·93) 7.15 (1.36) 
Natural indirect effect ≥5·6mmol/Lb  
+ 'natural' chance of diagnosis 
≥5·6mmol/Lb  
+ Not diagnosed 0·47 (0·23-0·96)  
      
aModels included the exposure (binary FPG concentration), mediator (clinical diagnosis of GDM), and all observed variables 455 
in the minimum sufficient adjustment set (maternal ethnicity, socio-economic circumstances, family history of GDM, height, 456 
weight, age, parity, previous histories of GDM and macrosomia, and smoking). 457 
bNICE criteria for diagnosis of GDM 458 
 459 
 460 
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Table 4 Estimated odds ratio for late stillbirth for different levels of FPG - with and without diagnosis 461 
and treatment for GDM - relative to (undiagnosed) women with FPG<4.1mmol/L  462 
FPG No diagnosis & treatment Diagnosed & treated 
     
 aORa (95% CI) aORa (95% CI) 
     
          
4·1 1·15 (1·01-1·30)   
4·6 1·46 (1·01-2·10)   
5·1 1·87 (1·02-3·42)   
5·6 2·39 (1·03-5·55) 0·61 (0·21-1·72) 
6·1 3·05 (1·03-9·02) 0·78 (0·26-2·34) 
6·6 3·89 (1·03-14·65) 1·00 (0·30-3·33) 
7·1 4·97 (1·04-23·80) 1·27 (0·33-4·90) 
7·6 6·34 (1·04-38·67) 1·62 (0·35-7·40) 
aModels included the exposure (continuous FPG concentration), mediator (clinical diagnosis of GDM), and all observed 463 
variables in the minimum sufficient adjustment set (maternal ethnicity, socio-economic circumstances, family history of 464 
GDM, height, weight, age, parity, previous histories of GDM and macrosomia, and smoking). 465 
 466 
